Can you take Nelarabine with Quadramet?
1 drug interaction and 7 additional warnings found for the following 2 drugs:
- nelarabine
- Quadramet (samarium sm 153 lexidronam)
Drug interactions
Major drug interactions
Major:
samarium sm 153 lexidronam nelarabine
Applies to: Quadramet (samarium sm 153 lexidronam) and nelarabine
Using samarium sm 153 lexidronam together with nelarabine may increase the risk of side effects that affect your bone marrow function, resulting in low numbers of different types of blood cells. You may be more likely to develop anemia, bleeding problems, or infections due to low blood cell counts. You should seek medical attention if you develop paleness, fatigue, dizziness, fainting, unusual bruising or bleeding, fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. Talk to your doctor if you have any questions or concerns. Your doctor may already be aware of the risks, but has determined that this is the best course of treatment for you and has taken appropriate precautions and is monitoring you closely for any potential complications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Food/lifestyle interactions
No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
Disease interactions
7 potential interactions Applies to: 7 conditions, including Liver Disease, Hyperuricemia Secondary to Chemotherapy, Neurological Disorders, Renal Dysfunction, and History, Radiation Therapy.
History, Radiation Therapy
Major:
nelarabine
Nelarabine has a major potential interaction with History, Radiation Therapy.
Severe neurologic adverse reactions have been reported with the use of nelarabine. Neurotoxicity is the dose-limiting toxicity of nelarabine. Patients treated previously or concurrently with intrathecal chemotherapy or previously with craniospinal irradiation may be at increased risk for neurologic adverse events. Close monitoring for neurologic adverse reactions is strongly recommended, when using nelarabine and therapy should be discontinued for neurologic adverse reactions of NCI Common Toxicity Criteria Grade 2 or greater.
Hyperuricemia Secondary to Chemotherapy
Moderate:
nelarabine
Nelarabine has a moderate potential interaction with Hyperuricemia Secondary to Chemotherapy.
Patients receiving nelarabine should receive intravenous hydration according to standard medical practice for the management of hyperuricemia in patients at risk for tumor lysis syndrome. Consideration should be given to the use of allopurinol in patients at risk of hyperuricemia.
Liver Disease
Moderate:
nelarabine
Nelarabine has a moderate potential interaction with Liver Disease.
The influence of hepatic impairment on the pharmacokinetics of nelarabine has not been evaluated. Because the risk of adverse reactions to this drug may be greater in patients with severe hepatic impairment (total bilirubin greater than 3 times upper limit of normal), it is recommended to closely monitor patients with severe liver dysfunction when treated with nelarabine.
Neurological Disorders
Major:
nelarabine
Nelarabine has a major potential interaction with Neurological Disorders.
Severe neurologic adverse reactions have been reported with the use of nelarabine. Neurotoxicity is the dose-limiting toxicity of nelarabine. Patients treated previously or concurrently with intrathecal chemotherapy or previously with craniospinal irradiation may be at increased risk for neurologic adverse events. Close monitoring for neurologic adverse reactions is strongly recommended, when using nelarabine and therapy should be discontinued for neurologic adverse reactions of NCI Common Toxicity Criteria Grade 2 or greater.
Renal Dysfunction
Moderate:
nelarabine
Nelarabine has a moderate potential interaction with Renal Dysfunction.
Nelarabine has not been studied in patients with renal dysfunction. There are insufficient data to support a dose recommendation for patients with a CrCl less than 50 mL/min. Because the risk of adverse reactions to this drug may be greater in patients with moderate (CrCl 30 to 50 mL/min) or severe (CrCl less than 30 mL/min) renal impairment, these patients should be closely monitored for toxicities if treated with this drug.
Tumor Lysis Syndrome
Moderate:
nelarabine
Nelarabine has a moderate potential interaction with Tumor Lysis Syndrome.
Patients receiving nelarabine should receive intravenous hydration according to standard medical practice for the management of hyperuricemia in patients at risk for tumor lysis syndrome. Consideration should be given to the use of allopurinol in patients at risk of hyperuricemia.
Vaccination
Major:
nelarabine
Nelarabine has a major potential interaction with Vaccination.
Immunocompromised patients receiving nelarabine should avoid receiving live vaccines.
Report options
More resources
nelarabine
A total of 338 drugs are known to interact with nelarabine.
- Nelarabine is in the drug class antimetabolites.
- Nelarabine is used to treat the following conditions:
Quadramet
A total of 223 drugs are known to interact with Quadramet.
- Quadramet is in the drug class therapeutic radiopharmaceuticals.
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.